01 Advancements in Intranasal Biologics and Peptide Drug Delivery The increasing development of biologics and peptide-based therapies is driving the transition toward advanced nasal drug delivery technologies capable of improving systemic absorption. Manufacturers are investing in novel permeation enhancers, nanoparticle formulations, and powder-based delivery systems to overcome bioavailability limitations. For example, ARS Pharmaceuticals developed neffy, an intranasal epinephrine spray, demonstrating the growing acceptance of nasal delivery for emergency systemic therapies.
02 Integration of Smart Nasal Delivery Devices with Digital Healthcare Platforms The growing adoption of connected healthcare is accelerating the transition toward smart nasal drug delivery devices that support treatment monitoring and patient adherence. Manufacturers are incorporating sensors, dose tracking capabilities, and wireless connectivity to improve medication compliance while generating real-time usage data for healthcare providers. This trend is strengthening personalized disease management by enabling remote monitoring, timely interventions, and data driven treatment optimization.
01 The nasal drug delivery technology market is moderately exposed to supply chain disruptions, as it depends on the timely availability of specialized pharmaceutical ingredients, precision delivery devices, packaging materials, and global manufacturing networks. Disruptions in raw material sourcing, component shortages, and transportation delays can affect production schedules, increase manufacturing costs, and delay product launches across multiple regions. The market is expected to follow a capacity-constrained recovery, supported by expanding manufacturing capacity, localized production initiatives, and gradual stabilization of global supply networks.
01 The nasal drug delivery technology market forecasts continued investment activity driven by the expanding pipeline of intranasal biologics and growing focus on nose-to-brain therapies.
02 Key Investment and Funding Activities in Nasal Drug Delivery Technology Market, 2025 Company Funding/Investment (USD) Details Mosanna Therapeutics USD 80 million (Series A) In 2025, Mosanna raised a Series A round led by EQT Life Sciences and Pivotal BioVenture Partners, with participation from Forbion, Broadview Ventures, and Norwest, to advance its intranasal spray for obstructive sleep apnea into Phase II clinical trials. ENA Respiratory USD 22.4 million (Series B) In October 2025, ENA raised Series B financing to advance INNA-051, a dry-powder antiviral nasal spray, into Phase II clinical development. The round included investments from the Gates Foundation, Flu Lab, Brandon Capital, Uniseed, and Stoic Venture Capital.
01 Commercialization of Intranasal Rescue Therapies and Demand for Needle-Free Vaccine & Immunization Platforms Drive the Market The increasing approval and commercialization of intranasal rescue therapies are driving demand for advanced nasal drug delivery technologies across emergency care. Pharmaceutical companies are expanding intranasal formulations for conditions requiring rapid therapeutic action, including opioid overdose, acute seizures, severe allergic reactions, and migraine. This is increasing demand for precision nasal spray devices capable of delivering accurate doses with fast systemic absorption.The increasing focus on needle-free vaccination is driving demand for nasal drug delivery technologies by providing a painless, easy-to-administer alternative to injectable vaccines. Intranasal vaccines can stimulate both mucosal and systemic immune responses, making them attractive for preventing respiratory infectious diseases while improving vaccination coverage. This has encouraged pharmaceutical companies and research organizations to invest in advanced intranasal vaccine formulations and delivery devices, increasing demand for specialized nasal drug delivery platforms.
01 Limited Dose Volume Capacity and High Manufacturing Complexity Restrain Market Expansion The nasal cavity can accommodate only a small volume of formulation per administration, typically around 100–150 µL per nostril, limiting the amount of drug that can be delivered effectively. This makes nasal delivery unsuitable for therapies requiring high doses or prolonged systemic exposure without repeated administration. As a result, the applicability of nasal drug delivery remains restricted for several therapeutic categories, limiting market expansion.Advanced nasal drug delivery products, particularly dry powder formulations, biologics, and preservative-free multidose sprays, require specialized manufacturing processes, aseptic production environments, and precision filling technologies. These requirements increase production costs, technical complexity, and quality control challenges for manufacturers.
01 Expansion of Self-Administration Therapies and Growth of Generic Nasal Drug Products Open New Revenue Avenues The shift toward self-administered therapies and decentralized healthcare creates an opportunity for nasal drug delivery technology providers. Increasing demand for convenient delivery of emergency medications and specialty therapies is driving adoption of easy-to-use nasal platforms. For example, the FDA approved RiVive (naloxone hydrochloride) nasal spray as an over-the-counter opioid overdose reversal treatment, expanding access to needle-free emergency medication delivery and strengthening opportunities for patient-friendly nasal drug delivery systems.The increasing expiration of patents for branded nasal medications creates an opportunity for nasal drug delivery technology providers and pharmaceutical manufacturers. Growing demand for affordable generic nasal sprays and combination therapies is encouraging the development of optimized formulations and efficient delivery devices. The availability of generic versions of intranasal corticosteroids for allergic rhinitis and sinusitis is increasing adoption of cost-effective nasal treatment options, creating future opportunities for advanced nasal delivery platforms.
01 Limited Compatibility with High-Viscosity and Maintaining Long-Term Stability Challenges Market Growth The limited ability of current nasal drug delivery systems to efficiently administer high-viscosity biologics, peptides, and large-molecule drugs creates a challenge for market growth. Formulation limitations can restrict the use of nasal routes for advanced therapies, reducing adoption among pharmaceutical developers.Maintaining drug stability, sterility, and performance throughout storage and transportation remains a key challenge for nasal drug delivery manufacturers. Temperature sensitivity, formulation degradation, and packaging requirements can increase production complexity and supply chain costs. These challenges are particularly significant for biologics and specialty therapeutics, where strict storage conditions are essential to preserve drug efficacy.
September 2025 Aptar Pharma announced an exclusive partnership with Dianosic to advance the Active Resorbable Intranasal Scaffold (ARIS) technology platform for chronic allergic rhinitis and chronic rhinosinusitis.